IL17A and infection: Cumulative evidence suggests that IL-17A-induced pathology is significant during late-stage disease rather than during early infection (3, 18, 19), however delineating IL-17A signaling during both stages could promote the development of specific immunotherapeutic interventions that target key molecules within this pathway, and in doing so, improve current treatment regimes.